Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow.
BASEL, Switzerland (PRWEB) November 12, 2019
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies, a clinical-stage biopharmaceutical company developing T-cell receptor (TCR)-based cancer immunotherapies, has adopted Genedata Biologics® to streamline their R&D operations related to the discovery and development of high-affinity and high-specificity T-cell receptors for adoptive cell therapies (ACT) and bispecific TCRs.
“We required a scalable software solution that is compatible with Immatics’ proprietary XCEPTOR® platform to facilitate the systematic analysis of our TCR data for our proprietary and partnered programs,” said Dominik Maurer, Ph.D., VP Immunology at Immatics. “Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow, including Immatics’ ACTengine®, ACTallo® and TCER® bispecific TCR molecule development. We expect Genedata Biologics to foster our internal information exchange and further increase our efficiency.”
Integrated E2E Workflow Platform for Cell & Gene Therapy
As highly engineered entities, bispecific molecules and cell and gene therapies pose new design, cloning, expression, purification, and analytics challenges. Genedata Biologics provides purpose-built functionality for the design and evaluation of large panels of novel cellular modalities, such as engineered TCRs and their variations. In particular, the platform enables the automation of screening, engineering, production, and testing of these innovative therapeutic modalities. The workflow platform handles next-generation molecule-specific designs in high throughput and includes dedicated tools for developability and manufacturability assessments. Genedata Biologics is an end-to-end (E2E) platform that streamlines the design, generation, validation, and unique identification of TCR- based molecules, resulting in more efficient evaluation and production.
“We are excited that Immatics, a leader in immuno-oncology, has selected Genedata as their partner,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are delighted that Genedata Biologics helps our customers to increase the efficiency of the discovery and development of novel gene and cellular therapeutics, and we will continue to invest in expanding the platform’s capabilities to address new technologies and requirements in this quickly evolving field.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
Phone: +41 61 511 85 61
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.